Custom crystal commemorating FDA approval of Gomekli, a treatment for the rare tumor disease ncurofibromatosis 1 (NF1). (25AZH094)
Custom crystal commemorating FDA approval of Gomekli, a treatment for the rare tumor disease ncurofibromatosis 1 (NF1). (25AZH094)
Crystal financial tombstone, featuring a sandblasted map of the world, recognizing a licensing and commercialization agreement between X4 Pharmaceuticals and Norgine. The agreement centers onthe drug Mavorixafor, and encompasses Europe, New Zealand, and Australia. (25LNL023)
Crystal deal toy commemorating a follow-on stock offering by Oculis. The Swiss biopharmaceutical company provides treatment for eye conditions such as diabetic macula edema and acute optic neuritis. (25AKL187)
Custom Lucite commemorative recognizing the first-in-human dose of a treatment for inflammatory lung diseases. (22ALJ326)
Logo-shaped Lucite tombstone, with a plexi bottom matched to a logo color, celebrating a licensing agreement between Arrowhead Pharmaceuticals and GlaxoSmithKline (GSK). The agreement centers on a treatment for liver disease. (22ALJ324)
Custom Lucite, incorporating an embedded vial, celebrating the first-in-human dosing in a Phase 1 clinical trial of cancer treatment developed by biotech company Immunome. (25ALJ040)
Custom Lucite celebrating the approval by the U.S. Food and Drug Administration (FDA) of the drug Crenessity. Crenessity was developed by Neurocrine Biosciences to treat a rare congenital adrenal condition. (25ALJ020)
Custom Lucite, incorporating an embedded vial of Imdelltra, celebrating the approval of the drug by the Food and Drug Administration (FDA). Developed by Amgen, Imdelltra treats small cell lung cancer, a condition that afflicts about 35,000 Americans annually. (24ALJ148)
Custom Lucite celebrating the first-in-human trial of SOR 102, a treatment for nflammatory bowel disease. The drug was developed by Utah-based Sorriso Pharmaceuticals. (23AKL435)
